Compare AENT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | AQST |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.7M | 809.3M |
| IPO Year | N/A | 2018 |
| Metric | AENT | AQST |
|---|---|---|
| Price | $7.73 | $5.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $8.83 |
| AVG Volume (30 Days) | 54.7K | ★ 2.3M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.70 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,088,441,000.00 | $43,397,000.00 |
| Revenue This Year | $7.29 | N/A |
| Revenue Next Year | $1.84 | $52.69 |
| P/E Ratio | $18.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $2.12 |
| 52 Week High | $11.57 | $7.55 |
| Indicator | AENT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 44.71 |
| Support Level | $7.07 | $5.61 |
| Resistance Level | $8.45 | $6.44 |
| Average True Range (ATR) | 0.55 | 0.31 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 64.02 | 16.44 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.